Lipagim 200 Agimexpharm medicine supplements the diet and treatment of hypertension of blood triglycerides (3 blisters x 10 tablets)

pharmacokinetics

No data.

Temporarily suspend medication.

Notify the doctor with unwanted effects when using the drug.

Be cautious when using

increased serum aminotransferase (AST, ALT) exceeded 3 times the normal level was notified at about 3% of the patient using fenofibrat. Chronic hepatitis and cholestatic hepatitis occur early after a few weeks or occurred late after a few years from the start of using fenofibrat, cirrhosis combined with chronic hepatitis is also notified in some rare cases. Periodic liver function must be monitored (every 3 months) in the first 12 months of treatment. If the concentration of aminotransferase serum exceeds 3 times the normal level, it is necessary to stop treating fenofibrat.

Fenofibrat, as well as other fibric acid conductors (such as Gemfibrozil), can increase cholesterol in bile, leading to gallstones. If the gallbladder checks with stones, it is necessary to stop fenofibrat.

Myalgitis, muscle diseases and/or muscle pepper have been announced in fenofibrat users or other fibric acid derivatives. Tieu Co Van and other complications have also been notified in patients using fenofibrat along with some other lipid medications, for example, statins (HMG-CoA Reductase inhibitors). Patients using Fenofibrat must be reported to report as soon as the muscle pain is unexplained, or sensitive to pain, weakness, especially if it is difficult to stay or fever. Periodic monitoring of Creatin Kinase (CK or CPK) must be monitored in patients with those side effects. Fenofibrat treatment must be stopped, if the serum CPK increases significantly or suspected or diagnosed as muscle or muscle disease.

A few rare cases of severe skin rash must be hospitalized and used corticosteroid therapy, including Stevens-Johnson syndrome and poisoned epidermal necrosis have been informed when using fenofibrat. The urticaria and skin rash have also been notified in about 1% of patients using Fenofibrat therapy.

Has caused pancreatitis in patients treated with fenofibrat or other fibric acid conductors.

A slightly and moderate reduction in hemoglobin, hematocrit and leukocytes have met in patients with fenofibrat. These parameters often return to normal during long -term treatment. A few rare cases of thrombocytopenia and grain leukemia during the tests have been marketed. It is necessary to periodically count hemoglobin in the first 12 months of treatment with fenofibrat.

Effects of fenofibrat on the incidence of disease and cardiovascular death rate or non -cardiovascular has not been defined. However, because fenofibrat chemical, pharmacological and clinical all are similar to other fibric acid derivatives, some unwanted effects of the clofibrate (currently no longer sold in the market) and Gemfibrozil, for example, the rate of gallstones, gallbladder inflammation requires surgery, complications after gallbladder removal, cancer, pancreatitis, cholecystic removal, and all -body deaths can also occur with Fenofiber. Thus, prudent things related to fibrat therapy should be monitored.

Safety and effectiveness of fenofibrat has not been determined in children under 18 years old.

The effect of the drug on driving and operating machinery

There is no evidence of the effect of the drug on the ability to drive and operate machinery.

Use drugs for women during pregnancy and lactation

Pregnancy:

Do not use during pregnancy because there is no data on use of drugs in pregnant women, should only be used if the benefits are superior to the risk.

Women who are likely to be pregnant or are using contraception or pregnancy should consult a doctor carefully before treatment with this drug.

There is no information on the toxicity on the fetus.

breastfeeding period:

No data. However, because of safety, should not be used for nursing mothers.

Interactive drug

Interaction of drugs with other drugs and other types of interactions:

Use a combination of HMG inhibitors with COA Reductase (for example: Pravastatin, Simvastatin, Fluvastatin) and Fibrat will significantly increase the risk of muscle lesions (such as increased creatin kinase, myoglobin urine, muscle pilot).

Combining fibrat with cyclosporin increases the risk of kidney toxicity caused by cyclosporin.

Fenofibrat increases the effects of anticoagulant oral medications, which increases the risk of bleeding due to pushing these drugs out of the position attached to plasma proteins. Need to monitor prothrombin more often and adjust the anticoagulant dose transparent

Fenofibrat treatment time and after 8 days of stopping the drug.

Complex resin with bile acid:

Because complex resines with bile acid can link other drugs to be used simultaneously,

Patients should use fenofibrat at least 1 hour ago or 4 to 6 hours after using resin

Completely created with bile acid to avoid obstructing the absorption of the drug.

colchicin:

Cases of muscle disease, including muscle pepper, have been reported when using fenofibrat at the same time as colchicin, need to be cautious when prescribing fenofibrat with colchicin.

Glitazon:

Some cases of reducing paradoxes with HDL cholesterol recovery have been reported during the use of fenofibrat at the same time as Glitazon. Therefore, it is necessary to monitor HDL cholesterol if one of these ingredients is added to the other and stop one of the two therapies if the HDL cholesterol is too low.

Medicines that affect the cytochrom P450 enzyme:

In vitro studies using microsom of human liver show that fenofibrat and fenofibric acid are not Cytochrom inhibitors (CYP) P450 CYP3A4, CYP2D6, CYP2E1 or CYP1A2. They are weak inhibitors CYP2C19 and CYP2A6, and mild to medium inhibitors CYP2C9 at treatment concentrations.

Patients with simultaneous use of fenofibrat and drugs are metabolized through CYP2C19, CYP2A6 and especially CYP2C9 with narrow treatment index should be carefully monitored and if necessary, the dose of these drugs should be adjusted.Other:

There is no clinical interaction proved between fenofibrat and other drugs reported, although In vitro interactive studies show the phenylbutazon movement from plasma protein -connected positions. Similar to other fibrats, Fenofibrat increases the multifunctional oxidation enzymes of mitochondria related to the metabolism of fatty acids in rodents and can interact with drugs metabolized by these enzymes.

The cavalry of the drug:

Due to the absence of studies on the correlation of the drug, not mixing this drug with other drugs.